RxDoctor Payments DataLook up a doctor →

Robert Chiascione, MD

Internal Medicine · Las Vegas, NVNPI 1710935697

Payments from drug & device makers

$174,231in general payments, 2019–2025

Across 1,225 payments — averaging $142.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$146K
  • AbbVie$6K
  • AstraZeneca$4K
  • Novo Nordisk$2K
  • Boehringer Ingelheim$2K
  • GSK$2K
  • plus $14K from 54 others

What the payments were for

  • Consulting fees$146,39884%
  • Food & beverage$27,14916%
  • Education$6840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Takeda Pharmaceuticals U.S.A., Inc.97$145,704
AbbVie(2 entities)191$5,529
AstraZeneca118$3,725
Novo Nordisk133$2,461
Boehringer Ingelheim61$1,536
GSK59$1,524
Biohaven Pharmaceuticals, Inc.11$1,464
Johnson & Johnson(2 entities)48$1,193
Astellas Pharma US Inc45$1,119
Lilly USA, LLC69$1,084
Amgen53$1,065
Bayer27$701
Pfizer36$679
Abbott18$482
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)15$403
Corcept Therapeutics17$402
Teleflex LLC3$398
Exact Sciences17$381
Sanofi-aventis U.S. LLC26$331
Otsuka America Pharmaceutical, Inc.16$289
Antares Pharma, Inc.17$254
Esperion Therapeutics, Inc.7$237
Amarin Pharma, Inc.16$216
Biohaven Pharmaceutical Holding Company Ltd.12$209
Merck16$204
Idorsia Pharmaceuticals US Inc5$188
Lundbeck LLC10$183
Viiv Healthcare Company5$177
Phathom Pharmaceuticals, Inc.3$164
Regeneron Healthcare Solutions, Inc.2$160
Alnylam Pharmaceuticals Inc.2$144
Sanofi1$129
Axsome Therapeutics, Inc.6$128
THD America, Inc.1$124
Kowa Pharmaceuticals America, Inc.8$121
Redhill Biopharma Inc.1$115
E.r. Squibb & Sons, L.L.C.5$112
Medtronic2$107
Novartis6$100
Dexcom, Inc.5$81
Teva Pharmaceuticals USA, Inc.4$61
Nabriva Therapeutics, PLC4$57
Endo Pharmaceuticals Inc.3$56
Eisai Inc.3$52
Edwards Lifesciences2$51
Almatica Pharma LLC2$46
IBSA Pharma Inc.2$30
Halozyme Inc2$28
Shield Therapeutics Inc1$25
Arbor Pharmaceuticals, Inc.2$24
Aimmune Therapeutics, Inc.1$22
Kyowa Kirin, Inc.1$21
Aytu Biopharma, Inc.1$21
Sunovion Pharmaceuticals Inc.1$20
Impel Pharmaceuticals Inc.1$20
Sumitomo Pharma America, Inc.1$19
Boston Scientific1$16
Currax Pharmaceuticals LLC1$15
Avanir Pharmaceuticals, Inc.1$15
Nalpropion Pharmaceuticals LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$174,231 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$59,088
Medicare patients
161
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$88,575
MounjaroTirzepatide40$54,666
JardianceEmpagliflozin46$48,088
FarxigaDapagliflozin Propanediol53$45,456
RybelsusSemaglutide44$44,698
XareltoRivaroxaban45$34,962
MyrbetriqMirabegron55$34,699
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$24,984
OzempicSemaglutide17$18,067
Synjardy XrEmpagliflozin/Metformin Hcl11$13,898
GlyxambiEmpagliflozin/Linagliptin20$13,226
BrilintaTicagrelor25$12,087
SymbicortBudesonide/Formoterol Fumarate34$10,787
VyvanseLisdexamfetamine Dimesylate20$10,388
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$679$90,235109 claims
AstraZenecaFarxiga, Brilinta, Symbicort, Breztri Aerosphere$3,725$76,906126 claims
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi$1,536$75,21277 claims
Novo NordiskRybelsus, Ozempic$2,461$62,76561 claims
Lilly USA, LLCMounjaro$1,084$54,66640 claims
Johnson & JohnsonXarelto$1,193$34,96245 claims
Astellas Pharma US IncMyrbetriq$1,119$34,69955 claims
GSKTrelegy Ellipta$1,524$24,98420 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$145,704$10,38820 claims
AbbVieSynthroid$5,529$7,77665 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →